Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Stock Is Getting Slammed Today

By George Budwell – Updated Sep 2, 2020 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An appeal hearing for Vascepa's patent case isn't sitting well with investors.

What happened

Shares of the mid-cap biopharma Amarin (AMRN 0.88%) plummeted by as much as 31% Wednesday on over 10 times the normal daily volume. The drugmaker's shares were tanking today in response to an appeals hearing over the patents for its heart medication Vascepa. 

Amarin's shares bounced off their lows of the day, but then closed today down almost 31%. 

A man with a look of shock on his face with a downward trending graph in the background.

Image source: Getty Images.

So what

Last March, Vascepa's patents were ruled invalid by a lower court, opening the door to generic rivals and possibly wiping billions in future revenue off the table. Since then, Amarin's stated goal has been to get this patent ruling reversed on appeal.

But Amarin's legal strategy seemingly took a big hit today. The three-judge panel handling the appeal reportedly had zero questions for the defendants Hikma Pharmaceuticals and Dr. Reddy's Laboratories. While it's impossible to say for certain why the judges didn't have any questions for the defendants, Wall Street took this as a bad sign for Amarin's chances of winning on appeal. 

Now what

Is Amarin's stock a bad-news buy? When Vascepa first grabbed its long-awaited label expansion as an add-on to statin therapy in patients with persistently high triglyceride levels late last year, Amarin's future appeared to be extremely bright. This first-of-its-kind heart medication seemed to have a real chance at generating mega-blockbuster sales (greater than $5 billion per year).

The company's fortunes, though, have taken a dramatic downturn in the wake of this adverse patent ruling. Amarin's stock may have a lot further to fall if the company can't catch a break during the appeals process. As such, it might be best to watch this biotech stock from the safety of the sidelines for now. 

George Budwell owns shares of Amarin. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Stock Quote
$1.15 (0.88%) $0.01
Dr. Reddys Laboratories Stock Quote
Dr. Reddys Laboratories
$55.39 (0.18%) $0.10
Hikma Pharmaceuticals PLC Stock Quote
Hikma Pharmaceuticals PLC
$14.29 (2.36%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.